The first stop for professional medicines advice

‘Biosimilar’

42 results

Preparing to use eculizumab biosimilar

6 March 2024Introducing biosimilar eculizumab needs planning.

Preparing to use ranibizumab biosimilar

29 June 2022Ranibizumab biosimilar needs planning.

Understanding biological and biosimilar medicines

29 June 2022Biosimilar medicines are a type of biological medicine that offer the NHS opportunities to deliver better

Preparing to use tocilizumab biosimilar

5 March 2024Introducing biosimilar tocilizumab needs planning.

Preparing to use natalizumab biosimilar

6 February 2024Natalizumab biosimilar needs planning.

Biosimilars Updates

material to support the introduction of adalimumab, eculizumab, natalizumab, ranibizumab and tocilizumab biosimilars

The licence and supporting evidence for natalizumab biosimilar

6 February 2024One licensed natalizumab biosimilar is available: Tyruko.

The licence and supporting evidence for tocilizumab biosimilar

5 March 2024One licensed tocilizumab biosimilar is available: Tyenne.

The licence and supporting evidence for ranibizumab biosimilar

29 June 2022Three licensed ranibizumab biosimilars are available: Byooviz, Ongavia and Ximluci.

The licence and supporting evidence for eculizumab biosimilar

6 March 2024Two licensed eculizumab biosimilars are available: Bekemv and Epysqli.